Mast Cell Leukemia
Associated Genetic Biomarkers
NCI Definition: A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001) 
There are 3 clinical trials for mast cell leukemia, of which 1 is open and 2 are completed or closed. Of the trials that contain mast cell leukemia as an inclusion criterion, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open).
FLT3 is the most frequent gene inclusion criterion for mast cell leukemia clinical trials .
Cd16/il15/cd33 trispecific killer cell engager, donor lymphocytes, and interleukin-2 are the most common interventions in mast cell leukemia clinical trials.
Significant Genes in Mast Cell Leukemia
FLT3 is an inclusion eligibility criterion in 1 clinical trial for mast cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and mast cell leukemia as inclusion criteria, 1 is phase 1 (0 open) .
Donor lymphocytes, interleukin-2, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in mast cell leukemia trials with FLT3 mutations as inclusion criteria .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.